Dapagliflozin — Dosing in CKD & Dialysis
Dapagliflozin (SGLT2 Inhibitor): renal dosing adjustments, dialyzability (Removal by hemodialysis has not been studied (Farxiga label section 10). Level estimated from molecule size or protein binding; not measured.), and renal-relevant safety risk for CKD and dialysis patients. Educational referenc
Reviewed by Matt · November 16, 2026